France Continuous Glucose Monitoring Market Size (2024 - 2029)

France Continuous Glucose Monitoring Market Analysis

The France Continuous Glucose Monitoring Market size is estimated at USD 366.36 million in 2024, and is expected to reach USD 585.21 million by 2029, growing at a CAGR of 9.80% during the forecast period (2024-2029).

Diabetes was considered a major risk factor for developing SARS-CoV-2 infections during the COVID-19 pandemic as it was associated with a higher risk of infections and a higher risk of developing severe forms of COVID-19-related pneumonia. Various underlying comorbidities, such as obesity, hypertension, cardiovascular diseases, chronic kidney disease, and immune dysfunction, were major factors susceptible to infectious complications. Following a COVID-19 infection, various studies suggested that reduced numbers of insulin secretory granules in beta cells and impaired glucose-stimulated insulin secretion were observed in the affected patients. In addition, post the pandemic, some patients developed insulin resistance and had elevated blood glucose levels, although they had no previous history of diabetes.

Continuous glucose monitoring (CGM) devices help people manage Type 1 or Type 2 diabetes with fewer fingerstick tests. A CGM device consists of a sensor that is inserted just under the skin and measures glucose levels 24 hours a day. A transmitter sends results to a wearable device an integrated insulin pump, a smart insulin pen, or a cell phone to help provide actionable insights. Tracking blood glucose levels assists diabetes patients with the insulin required by the body and when to prevent high (hyperglycemia) or low (hypoglycemia) blood sugar levels, which can have serious side effects and even be life-threatening when not treated quickly.

Diabetes is associated with a higher risk of many health complications. People with diabetes face a higher chance of experiencing serious complications. While comparing the population with diabetes with those without diabetes, people with diabetes have an increased risk of being hospitalized and, thus, are expected to incur more healthcare expenses than non-diabetic people. Thus, it is essential for diabetics to effectively monitor and manage their blood sugar levels through technologies such as continuous glucose monitoring. Moreover, the reimbursement policy and the pricing policy in France are highly regulated, which drives the market and increases the adoption rate of new and advanced technologies.

Further, in France, the health insurance support service Sophia provides self-management education for adults living with diabetes, which helps people living with diabetes to better understand their conditions and ways to manage them, adjust their lifestyle to reduce the risk of complications and improve the quality of life. The Fédération Française des Diabétiques provides peer-to-peer support through a dedicated BPE service (bénévole patient expert). Thus, owing to the aforementioned factors, the market for continuous glucose monitoring diseases is expected to witness growth over the forecast period.

France Continuous Glucose Monitoring Industry Segmentation

Continuous glucose monitoring devices are used to diagnose both hyperglycemic and hypoglycemic conditions in diabetic patients throughout the day. The France continuous glucose monitoring market is segmented into components (sensors and durables (receivers and transmitters)). 

The report offers the value (in USD) and volume (in units) for the above segments.